Jafet Sola Alvarez Diagnosed With Grade 4 Brain Tumor in Freiburg
An orange-sized brain tumor discovered in February 2024 has upended the life of Jafet Sola Alvarez, a 36-year-old pub owner in Freiburg, Germany. Sola Alvarez, who operates the Litfass bar in the city’s Sedanviertel district, faces an aggressive recurrence of the disease requiring a self-funded peptide vaccination costing 70,000 euros.
The initial diagnosis came after Sola Alvarez experienced sudden discomfort and a tingling sensation in his left hand while returning from a neighborhood walk with his wife, Jana-Maylin vom Berg, and their two children. Doctors at the University Medical Center Freiburg discovered the tumor had already grown into surrounding healthy brain tissue. Surgeons successfully removed the visible tissue two months later, and subsequent pathology identified it as a grade 2 astrocytoma. Following the operation, Sola Alvarez took medication to delay recurrence and resumed normal activities, welcoming another child with vom Berg in 2025.
Sola Alvarez Treats Grade 4 Astrocytoma Recurrence
In July 2026, roughly two years after the initial surgery, Sola Alvarez suffered epileptic seizures that revealed a tumor recurrence. Medical evaluations classified the new growth as a grade 4 astrocytoma, the most severe category of brain cancer. Because the tumor sits in close proximity to critical blood vessels, surgeons could not remove the entire mass during an operation in late July.
Sola Alvarez began a course of radiation and chemotherapy at Heidelberg University Hospital in late August. Doctors in Heidelberg utilized a high-precision ion beam therapy designed to protect healthy tissue surrounding the treatment site more effectively than conventional radiation. The 36-year-old patient was scheduled for discharge from the hospital on a Friday.
Crowdfunding Campaign for Peptidic Vaccination
Faced with the high risk of further recurrence from the aggressive grade 4 tumor, vom Berg researched alternative therapies and identified a peptide vaccination developed by researchers at the German Cancer Research Center, Mannheim University Medical Center, and Heidelberg University Hospital. The treatment is designed to train the patient’s immune system to target cancer cells specifically. Clinical studies cited by vom Berg indicated that two-thirds of participants remained alive eight years post-treatment, compared to a median survival time of 2.5 to 5 years in older studies of similar aggressive tumors.
Because the clinical trial has concluded and the therapy has not been proven effective, statutory health insurance does not cover the 70,000-euro cost of the vaccination. To bridge this financial gap, vom Berg launched a crowdfunding campaign three weeks prior to reporting, which has raised over 54,000 euros.
“Wir hoffen, dass wir das benötigte Geld in ein paar Wochen zusammen haben,”
Jana-Maylin vom Berg regarding the fundraising effort.
Keep reading